<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Allergy</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Allergy</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский Аллергологический Журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1810-8830</issn><issn publication-format="electronic">2686-682X</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">733</article-id><article-id pub-id-type="doi">10.36691/RJA733</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">THERAPEUTIC APPROACHES TO THE URTICARIA TREATMENT</article-title><trans-title-group xml:lang="ru"><trans-title>ТЕРАПЕВТИЧЕСКИЕ ПОДХОДЫ К ЛЕЧЕНИЮ КРАПИВНИЦЫ</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Shvets</surname><given-names>S M</given-names></name><name xml:lang="ru"><surname>Швец</surname><given-names>С М</given-names></name></name-alternatives><email>smshvets@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Institute of Immunology</institution></aff><aff><institution xml:lang="ru">ФГБУ «ГНЦ Институт иммунологии» ФМБА России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2012-04-15" publication-format="electronic"><day>15</day><month>04</month><year>2012</year></pub-date><volume>9</volume><issue>2</issue><issue-title xml:lang="en">NO2 (2012)</issue-title><issue-title xml:lang="ru">№2 (2012)</issue-title><fpage>61</fpage><lpage>64</lpage><history><date date-type="received" iso-8601-date="2020-03-10"><day>10</day><month>03</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2012, Pharmarus Print Media</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2012, Фармарус Принт Медиа</copyright-statement><copyright-year>2012</copyright-year><copyright-holder xml:lang="en">Pharmarus Print Media</copyright-holder><copyright-holder xml:lang="ru">Фармарус Принт Медиа</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2014-12-15"/></permissions><self-uri xlink:href="https://rusalljournal.ru/raj/article/view/733">https://rusalljournal.ru/raj/article/view/733</self-uri><abstract xml:lang="en"><p>Urticaria is a heterogenic disorder, requires elimination of triggers and symptomatic treatment. The basic medications are antihistaminics of the second generation.</p></abstract><trans-abstract xml:lang="ru"><p>Крапивница — гетерогенное заболевание, требующее элиминации этиологических факторов и симптоматического лечения. Препаратами выбора являются неседативные антигистаминные препараты 2-го поколения.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>крапивница</kwd><kwd>антигистаминные препараты</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>EAACI/GA2LEN/EDF/WAO guideline: management of urticaria Allergy. 2009, v. 64, р. 1427-1443.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Российский национальный согласительный документ. Крапивница и ангиоотек. Рекомендации для практических врачей. М., «Фармарус Принт Медиа», 2007, 128 с.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>EAACI/GA2LEN/EDF guideline: management of urticaria Allergy. 2006, v. 61, p. 321-331.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>EAACI/GA2LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy. 2009, v. 64, р. 1417-1426.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Church M.K., Mauer M., Simons F.E. et Risk of first-generation H,-antihistamines: a GA2LEN position paper. Allergy 2010, v. 65, p. 459-466.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Гущин И.С. Аллергическое воспаление и его фармакологический контроль. М., «Фармарус Принт». 1998, 252 с.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Gillman S., Gillard M., Strolin Benedetti M. The concept of receptor occupancy to predict clinical efficacy: a comparison of second generation H,-antihistamines. Allergy Asthma Proc. 2009, v. 30 (4), p. 366-376.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Jauregui I., Ferrer M., Montoro L. et al. Anyihistamines in the treatment of chronic urticaria. J. Investig. Allergol. Clin. Immunol. 2007, v. 17, Suppl. 2, p. 41-52.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Nettis E., Colanardi M.C., Barra L. et al. Levocetirizine in the treatment of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. J. Dermatol. 2006, v. 154 (3), p. 533-538.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Potter P.C., Kapp A., Maurer M. et al. Comparison of the efficacy of levocetirizine 5 mg and desloratadine 5 mg in chronic idiopathic urticaria patients. Allergy. 2009, v. 64 (4), p. 596-604.</mixed-citation></ref></ref-list></back></article>
